About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT04655794

Clinical Analysis of Safety in Latent Tuberculosis Infection Prophylaxis Treatment

The treatment of latent TB with 3HP is an important issue for the prevention of active TB. However, significant proportion of subjects receiving 3HP had adverse reaction. The main purpose of this obse...

Lead sponsor: Chang Gung Memorial Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Tsai-Yu Wang

CONTACT

+886975368076 [email protected]

Sponsors

Lead Sponsor

Chang Gung Memorial Hospital

Age

20 - 100 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•close contact with active TB patients
•patients with autoimmune diseases preceding biological therapy
•health-care workers
•other clinical conditions, which increased the risk of LTBI. LTBI was confirmed by QuantiFERON-TB Gold In-Tube test (QFT-GIT; Qiagen, Valencia, CA, USA) with a cut-off value of 0.35 IU/ml.

Exclusion Criteria

•age less than 20 years
•pregnant women
•active TB or suspected active TB in the clinical evaluation
•severe liver disease
•ESRD
•organ transplantation
•close contact with a multidrug-resistant TB patient
•obesity (BMI\>30 Kgw/m2) and other conditions inappropriate for participation in this study as judged by the investigators.

Related studies

Intensive Monitoring Scheme of Lidocaine Cataplasms

NCT05645302 · Adverse Reaction to Drug

Assessment of Immediate Adverse Reactions From Dotarem in Children Under 2 Years of Age

NCT02609919 · Adverse Reaction to Drug, Allergic Reaction to Contrast Media

Personal Health Records and Elder Medication Use Quality

NCT02012712 · Adverse Reaction to Drug, Health Behavior, and more

COMPLETEDPhase 2

Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence

NCT02447679 · Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, and more

Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients

NCT00817375 · Depression, Adverse Reaction to Drug

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 7, 2020Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment500

Start dateApr 2018

Last updatedDec 7, 2020

Condition

Adverse Reaction to Drug 3HP

Locations shown

Institutional Review Board Chang Gung Medical Foundation

Taipei

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 7, 2020Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions